Study Objective: Established fasting guidelines for analgesia and sedation are difficult to follow in the emergency department (ED), and the association between preprocedural fasting and adverse events has been questioned. We characterize the fasting status of patients receiving procedural sedation and analgesia with nitrous oxide (N 2 O) in a pediatric ED and assess the relationship between fasting status and adverse events. Methods: A prospective case series was conducted in a children's hospital ED over an 8-month period. Patients receiving N 2 O for procedural sedation and analgesia were enrolled and followed up by telephone call. Preprocedural fasting state and adverse events, as well as N 2 O concentration, adjunctive drugs, and deepest level of sedation, were recorded. Adverse events were analyzed in relation to fasting status. Results: Two hundred twenty children who underwent procedural sedation and analgesia with N 2 O were enrolled. Fasting status was obtained in 218 patients (99.1%). Of these, 155 (71.1%; 95% confidence interval [CI], 64.5%-77.0%) did not meet fasting guidelines for solids There were no serious adverse events and no episodes of aspiration (1-sided 97.5% CI, 0% -1.7%). While in the ED, 46 minor adverse events occurred in 37 patients (16.8%; 95% CI, 12.1% -22.4%). Emesis occurred in 15 patients (7%), including 4 (6.3%; 95% CI, 1.8% -15.5%) of 63 patients who met and in 11 (7.1%; 95% CI, 3.6%-12.3%) of 155 patients who did not meet fasting guidelines for solids. There was no significant difference in median fasting duration between patients with and without emesis. Conclusion: Seventy-one percent of patients undergoing ED procedural sedation and analgesia with N 2 O did not meet established fasting guidelines. In this series, there was no association between preprocedural fasting and emesis. There were no serious adverse events.
T he American Academy of Pediatrics (AAP) 1, 2 and the American Society of Anesthesiologists (ASA) 3, 4 have published consensus-based preprocedural fasting guidelines for diagnostic and therapeutic procedural sedation. These guidelines are difficult to follow for nonelective emergency department (ED) procedures requiring sedation and analgesia, in particular, in children who are often not fasted and require urgent or emergent procedures.
Data on fasting state and ED procedural sedation and analgesia are limited, but recent studies 5 -10 have indicated that there is no association between preprocedural fasting and adverse events. The relationship between fasting status and adverse events during procedural sedation and analgesia with nitrous oxide (N 2 O) has not been studied.
The primary objective of our study was to characterize the fasting status of patients receiving procedural sedation and analgesia with N 2 O in a pediatric ED. Secondary objectives included assessing the relationship of preprocedural fasting state, N 2 O concentration, and depth of sedation with observed adverse events.
METHODS
We conducted a prospective observational study in the ED of a large urban children's hospital with an annual ED census of 60,000 patients.
All children presenting to the ED from August 2003 to March 2004 who underwent procedural sedation and analgesia with N 2 O were eligible for enrollment. There were no formal exclusion criteria. This study was approved by the hospital institutional review board.
When a child required procedural sedation and analgesia with N 2 O, the examining doctor informed one of the researchers or trained research assistants. Informed verbal consent was obtained and recorded together with arrangements for a follow-up phone call. N 2 O sedations were performed by ED medical and nursing staff based on published departmental guidelines 11 which do not specify a defined fasting time for N 2 O. N 2 O was administered by inhalation of a gas mixture with O 2 . The administration was available in 2 forms, demand valve fixed 50% N 2 O/50% O 2 , marketed as Entonox (BOC Ltd, North Ryde, NSW, Australia), and the continuous-flow system via the Quantiflex (BOC Ltd) MDM machine, which delivers 0% to 70% N 2 O and includes a scavenging system to decrease environmental contamination. Procedural sedation and analgesia with any agent in the ED are performed using standardized presedation assessment, monitoring during the procedure, and postsedation discharge criteria.
A clinical report form was developed to record data before, during, and after procedural sedation and analgesia with N 2 O. This included age, past medical problems, ASA class, time of injury (if applicable), procedure, drugs used in addition to N 2 O, fasting times for solids and liquids, highest concentration of N 2 O used, and deepest level of sedation.
The dietary history section of the questionnaire included date, time, and type and amount of last solid and clear liquid intake. In keeping with established AAP/ASA guidelines, 1 -4 solids were defined to include nonclear liquids such as infant formula, breast milk, and nonhuman milk. Clear liquids included but were not limited to water, fruit juices, carbonated beverages, clear tea, and black coffee. Preprocedural fasting duration of the patients for solids and clear liquids was compared with the established ASA guidelines to determine the extent of compliance with these guidelines. ASA guidelines recommend a fasting time of 6 hours for solids and 2 hours for liquids in children older than 6 months. 3, 4 Patients were classified according to ASA physical status classification (class 1, normal healthy patient; class 2, patient with mild systemic disease with no functional limitation; class 3, patient with severe systemic disease with definite functional limitation; 4, patient with severe systemic disease that is a constant threat to life; and 5, moribund patient who is not expected to survive without the operation).
To measure the level of sedation, a sedation scale developed and validated at the Children's Hospital of Wisconsin 9 was used. The scale has 7 levels of sedation ranging from 6 to 0 (6, anxious, agitated or in pain; 5, spontaneously awake without stimulus (talking); 4, drowsy, eyes open or closed, but easily arouses to consciousness with verbal stimulus; 3, arouses to consciousness with moderate tactile or loud verbal stimulus; 2, arouses slowly to consciousness with sustained painful stimulus; 1, arouses, but not to consciousness, with painful stimulus; and 0, unresponsive to painful stimulus). Depth of sedation was assessed on an ongoing basis during the procedure; the deepest level of sedation was recorded on the clinical report form.
Adverse events were defined a priori as serious or mild. Serious adverse events included oxygen desaturation less than 95%, apnea, stridor, airway misalignment requiring repositioning, laryngospasm, bronchospasm, cardiovascular instability, pulmonary aspiration, unplanned hospital admission, endotracheal intubation, permanent neurological injury, or death. Inadequate sedation was not regarded as an adverse event.
Patients were followed up by telephone within 72 hours by one of the researchers to examine the incidence of adverse events after discharge from the ED.
The electronic ED log was reviewed daily for patients who received procedural sedation and analgesia with N 2 O who were not included in the study.
All data were entered into SPSS software version 11.5 for Windows (SPSS, Inc, Chicago, Ill) for statistical analysis. Data were analyzed by using descriptive statistics, 
RESULTS
Two hundred twenty patients (age range, 14 months to 17 years; with a median age of 8 years and 3 months) undergoing procedural sedation and analgesia with N 2 O were enrolled during the 8-month data collection period. One hundred thirty-two patients (60.0%) were boys. Two hundred seven patients could be contacted for a follow-up call. According to the ASA physical status classification system, 209 patients (95.0%) were classes 1 and 2, and 11 patients (5.0%) were class 3. There were no class 4 or 5 patients.
The proportion of patients receiving various N 2 O concentrations is listed in Table 2 . The most frequent indications were orthopedic procedures (44.6%), laceration repair (21.4%), and vascular access procedures (18.2%). Of the 15 patients who underwent more than one procedure, 12 had additionally an intravenous (IV) line placed, and 3 had a plaster or backslab applied.
Some patients received other drugs in addition to N 2 O. Adjunctive drugs are listed in Table 3 . Lignocaine infiltration (20.0%) was the most frequent local agent, and morphine (12.3%) was the most frequent systemic agent.
Depth of sedation was observed during procedural sedation, and the deepest level of sedation was recorded in 218 patients (99.1%; Table 4 ). The majority of patients had scores in a range equivalent to moderate sedation (depth of sedation scores 4 and 5). Fifteen patients (6.9%) were deeply sedated (depth of sedation scores, 0-3); 2 of which had 
Fasting Status
Of the 220 patients who underwent procedural analgesia and sedation with N 2 O, accurate fasting status was obtained in 218 patients (99.1%; Fig. 1 
Adverse Events
None of the 220 patients in this study had a serious adverse events, and no airway manipulations, intubations, or unplanned admissions were required. There were no cases of desaturation or clinically apparent pulmonary aspiration (1-sided 97.5% CI, 0% -1.7%). Thirty-seven patients (16.8%; 95% CI, 12.1% -22.4%) experienced 46 mild adverse events in the ED (Table 5 ). Nine patients experienced more than one mild adverse event. All adverse events were mild and temporary. The most common adverse event was emesis in 15 (6.8%). Of these, 12 patients (80%) Some patients had more than one adjunctive drug. ALA indicates amethocaine, lignocaine, and adrenaline (topical); AnGel, amethocaine 4% (topical). vomited during N 2 O administration itself; the rest vomited after the procedure was completed and before discharge.
Median age for patients with adverse events in the ED was 106 months (IQR, 73-142), and for patients without adverse events, 94 months (IQR, 62 -131; P = 0.20). Median age for patients with emesis was 93 months (IQR, 63 -134), and for patients without emesis, 100 months (IQR, 63 -133 months; P = 0.98).
Patients who received 70% N 2 O vomited twice as often (7.7%) as patients receiving 50% N 2 O (3.6%; Table 1 ). However, when comparing 70% N 2 O versus either 50% or 60% N 2 O, the difference in the rate of adverse events (P = 0.71) or vomiting (P = 0.47) was not statistically significant.
A summary of the patients who vomited is listed in Table 6 . Of the 15 patients who vomited in the ED, 12 vomited during the procedure, and 8 had received more than 10 minutes of N 2 O administration before vomiting. However, patients vomited as early as 1 minute after commencing N 2 O administration. Fourteen patients received 70% N 2 O. Four received additional codeine or morphine.
There was no clear pattern in the relationship between adverse events and the type of procedure as shown in Table 2 .
The adverse events rate for each drug regimen is listed in Table 3 . There was no association between the addition of other drugs to N 2 O and adverse events (P = 0.55) or vomiting (P = 0.91).
When comparing patients who achieved a sedation score of 3 or less (deep sedation) with patients with a depth of sedation score more than 3, there was no association between depth of sedation and adverse events (P = 0.75) or vomiting (P = 0.31; Table 4 ).
Adverse Events and Fasting Status
There was no statistically significant difference in emesis rate in patients who met and did not meet fasting guidelines. Emesis in the ED occurred in 4 (6.3%; 95% CI, 1.8% -15.5%) of 63 patients who met and in 11 (7.1%; 95% CI, 3.6% -12.3%) of 155 patients who did not meet fasting guidelines for solids (P = 0.84). Likewise, there was no significant difference in the fasting duration of patients with and without emesis. For solids, median fasting duration for patients with emesis was 4.2 hours (IQR, 2.92-6.2), and without emesis, 4.4 hours (IQR, 3.0 -6.6; P = 0.63). For liquids, median fasting duration for patients with emesis was 3.8 hours (IQR, 2.5-6.2), and without emesis, 4.0 hours (IQR, 2.2-6.4; P = 0.77).
A visual breakdown of fasting duration (for both solids and clear liquids) in 2-hour increments with associated numbers of cases of adverse events and emesis is depicted in Figure 1 . Between 0 and 8 hours, cases of adverse events and emesis are distributed evenly throughout the different fasting durations, highlighting the observed lack of association between preprocedural fasting state and adverse events.
Follow-up
Of the 207 patients (94.1%) with follow-up phone call, 37 patients (17.9%) experienced 44 mild adverse events after discharge. The most frequent adverse events experienced were nausea (12; 5.8%), emesis (8; 3.6%), and nightmares (7; 3.4%; Table 5 ). Table 5 also shows the distribution of patients who experienced side effects at any time whether in the ED or after discharge. It shows that overall emesis (9.5%), nausea (7.3%), and dizziness (7.3%) were the most frequent adverse events experienced by patients. Of the 15 
LIMITATIONS
This study has several limitations. Despite being the largest series of ED use of N 2 O, one of the main limitations is the small number of patients enrolled relative to the frequency of serious adverse events. In our study, there were no serious adverse events and, in particular, no pulmonary aspirations. Pulmonary aspiration is a very rare event, and in general anesthesia, a recent study 12 calculated the pooled incidence of aspiration to be 1:3420. In a review of pediatric sedations in various settings over 27 years, Cote et al 13 found no cases of pulmonary aspiration. Hoffman et al, 9 in a hospitalwide study of 960 pediatric sedations, described 2 cases of aspiration, although outside the ED, in fasted patients. In 1014 procedural sedations in a pediatric ED using various agents, 68 patients (6.7%) experienced adverse events, but there were no aspirations. 5 At this time, there are no data to indicate the frequency of pulmonary aspiration in procedural sedation and analgesia with N 2 O. Although emesis is a limited proxy for pulmonary aspiration, we undertook a sample size calculation of the patients needed to show a difference in emesis rates for patients who met and who did not meet fasting guidelines. The calculations were limited by the lack of available data on fasting status and N 2 O use and emesis rate and variable concentration N 2 O use (50% -70%). However, assuming an emesis rate of 5% for fasted and 10% for unfasted patients and a distribution of 30% patients in the fasted and 70% in the unfasted group, 1080 patients would have been required to detect a difference at 80% power with an a level of 0.05. This would have required several years of data collection and would not have been feasible. In addition, the results of our study indicate an even smaller difference in the emesis rate between fasted and unfasted patients. Therefore, an even larger number of patients would be necessary for this study to be sufficiently powered to detect a difference between the fasted and unfasted patients.
Another limitation of this study is that a number of procedures under N 2 O during the study period were missed. This was mainly due to a limited availability of research assistants and researchers in the ED and the dependence on ED clinicians to complete the data collection tools in their absence. Based on a review of the electronic ED log, 60 eligible patients were not enrolled during the study period. The age distribution and diagnosis of unenrolled patients were similar to the study group, although data on fasting times and adverse events could not be ascertained in the missed patients. However, there were no serious adverse events, endotracheal intubations, or unexpected admissions of unenrolled patients.
We did not explore why clinicians fasted some patients longer than others beyond availability of staff and equipment. Although current departmental guidelines 11 do not specify a defined fasting time for N 2 O, it is possible that clinicians deliberately fasted some patients longer than others for a variety of reasons introducing a potential source of bias.
Furthermore, not all patients were followed up mainly because parents were unavailable for telephone follow-up or rarely because they did not give their permission to call.
DISCUSSION
Consensus-based AAP/ASA guidelines for procedural sedation and analgesia have been widely disseminated, 1 -4 but the guidelines are difficult to follow in the ED setting, and data in the medical literature to support their use in the ED are lacking. 12, 14 The high percentage of ED patients undergoing procedural sedation and analgesia not conforming to sedation guidelines has recently been documented in a large series. 5 We studied the fasting status of children receiving ED procedural sedation and analgesia with N 2 O, which has not been studied before.
We found that 66% of the 218 patients with documented dietary history who underwent procedural sedation and analgesia with N 2 O did not meet AAP/ASA preprocedural fasting guidelines. Many studies of N 2 O use as a procedural agent do not include fasting information. 15 -22 In 2 studies that used 50% N 2 O, patients were not fasted 23, 24 ; in 3 studies using 30% to 50% N 2 O, patients were fasted for 2 hours, 25 -27 and in 1 study of 50% to 70% N 2 O, patients were fasted for 4 hours for solids and 2 hours for clear liquids. 28 None of these studies have investigated the relationship between fasting status and adverse events. In our study, fasting status was not related to adverse events. This adds to a small but growing body of literature, indicating a lack of association between fasting status and adverse events in procedural sedation and analgesia. Agrawal et al 5 found that, in 905 pediatric ED patients, 56% were not fasted according to AAP/ASA guidelines and that there was no significant difference in median fasting duration between patients with and without adverse events and between patients with and without emesis. Only 14 of these patients had received N 2 O. In a study of 2085 pediatric ED patients receiving parenteral sedation, Roback et al 10 found that the incidence of adverse events was unrelated to fasting duration. In a study of 260 pediatric ED patients undergoing orthopedic procedures with fentanyl/ midazolam or ketamine/midazolam, mean fasting duration for patients with emesis was 4.4 ± 2.5 hours compared with 5.0 ± 2.4 hours for those without emesis (P = 0.40). 8 In a study of 257 children undergoing ED procedural sedation with IV ketamine, 30 children had fasted for less than 1 hour; 100, 1 to 2 hours; and 127, longer than 3 hours. There was no emesis during the procedures, but emesis rates after the procedure increased with increased fasting duration from 6.6% to 14% to 15.7%, respectively, although this was not statistically significant. 6 In a retrospective study of 324 children undergoing sedation with chloral hydrate for echocardiography fasting for less or longer than 120 minutes did not lead to a statistically significant difference in the rate of emesis (P = 0.74). 7 In a hospitalwide study of 960 pediatric patients undergoing procedural sedation with a range of agents (not including N 2 O), 9 adherence to preprocedural fasting guidelines did not affect the overall risk of complications.
Our study, the largest series of ED use of N 2 O to date, indicates that this is a safe agent for procedural analgesia and sedation without serious adverse events and with a low rate of temporary mild adverse events. In a number of pediatric studies with N 2 O concentrations ranging from 30% to 70%, no serious adverse have been reported. 15 -18,20 -30 In a large French survey series of 7571 children receiving demand valve 50% N 2 O, a major adverse events rate of 0.3% is reported without specific details, although all adverse events resolved within minutes, and no patient needed airway intervention. 19 Minor adverse events are reported at variable rates. The French study mentioned reported a minor adverse events rate of 5%, 19 and the same group reported a minor adverse events rate of 37% and an emesis and nausea rate of 3.7% in 1019 children in a further study of demand valve 50% N 2 O. 18 Henderson et al 21 reported a mild adverse events rate of 0% for 50% N 2 O and 28% for 70% N 2 O with no emesis in 39 and 43 children, respectively. The emesis rate of 7% in the ED in our study is similar to other reports. 17, 25, 28 We found that a not negligible number of our patients had mild adverse events after discharge. In particular, 5% of patients vomited after discharge. This needs to be communicated with parents. Most studies of N 2 O as an agent for procedural sedation and analgesia do not include follow-up information. 16 -24,26 -29 One study provides follow-up data after N 2 O use as an agent for ED procedural sedation and analgesia. Luhmann et al 25 found no emesis after discharge in 103 patients who received continuous-flow 50% N 2 O with or without midazolam.
We also found that N 2 O caused deep sedation in 7% of patients undergoing procedural sedation and analgesia, a higher rate than previously reported. A limited number of studies of N 2 O assess and report depth of sedation using a variety of assessment tools. 15, 16, 18, 19, 25, 26, 28, 29 In 46 patients receiving 30% N 2 O, none were sleepy or oversedated. 26 In 170 patients receiving continuous-flow 40% N 2 O, all patients were conscious and responsive to verbal contact on a 6-point sedation scale. 15 In the 2 large French series of demand valve 50% N 2 O, 25 (0.33%) of 7511 children were described as having a major adverse event including oversedation (defined as a loss of verbal contact), 19 and in the series of 1019 sedations, 2.1% were deeply sedated. 18 This was categorized as a minor adverse event, and depth of sedation was not further defined. 18 In 51 patients receiving continuous-flow 50% N 2 O, 14 were found to be awake, 34 responsive to voice, 3 responded to pain, and none were unresponsive based on AVPU scores (alert, responsive to voice, responsive to pain, and unresponsive). 25 In 40 patients receiving continuous-flow 50% N 2 O, no patients were unrousable (0) or asleep but rousable 1 based on a 0-to 3-point sedation scale. 16 Kanagasundaram et al 28 using continuous-flow 50% to 70% N 2 O in 90 children, using the same scoring system, found 1% of patients to be asleep but rousable (1) and none to be unrousable (0). In a study of 82 patients either receiving 50% or 70% N 2 O, none lost consciousness. 21 Clinicians using N 2 O in the ED setting at concentration greater than 50% need to be aware of and prepare for the potential to cause deep sedation. There were no serious adverse events in more deeply sedated patients in our study, but deeper sedation in general has been found to be associated with an increased risk of adverse events. 5, 9 In a study of 25 children receiving 20% to 65% N 2 O, Roberts and Wignall 31 found that the laryngeal reflex was maintained when radiopaque material was placed on the tongue during dental procedures. However, the combination of deep sedation and intraprocedural emesis theoretically conveys a high risk of aspiration.
In summary, we characterized fasting state and adverse events in procedural sedation and analgesia in the ED setting. We found that the majority of patients who were sedated were not fasted according to AAP/ASA fasting guidelines for procedural sedation and analgesia, and noncompliance with these guidelines did not affect the rate of adverse events, including emesis. Procedural sedation and analgesia with N 2 O when embedded in comprehensive presedation and postsedation management by trained ED staff result in a low adverse events rate.
